SUBJECT INDEX

A

Abnormal involuntary movements
  levodopa therapy and, 116-17
Acephate
  immunotoxicity of, 37
Acetaminophen
  discovery of, 431
  extracorporeal removal of, 183-84
  overdose of, 169
Acetylcholine
  adenosine and, 326
  atonia and, 142-43
  calcium channels and, 352
  corelease of, 60
  cortical desynchronization and, 140
  cotransmission of, 53-57
  organization of, 138-39
  ponto-geniculo-occipital waves and, 141-42
  rapid eye movements and, 140-41
  REM sleep and, 139-46
Acetylcholine receptor
  kinetic analysis of, 219
  models for, 199
Acetylcholinesterase
  cholinergic neurons and, 138-39
Acetyl-CoA
  carnitine and, 258-60
N-Acetylcysteine
  acetaminophen overdose and, 183
  methylmercury poisoning and, 188
N-Acetylprocainamide
  extracorporeal removal of, 185
Achalasia
  calcium channel blockers and, 347
Acidemias
  organic
    carnitine and, 262-63
Acquired immune deficiency syndrome
  adenosine and, 333
Actinidin
  structure of, 195
Actinomycin D
  intercalation and, 195-96
Adenine nucleotides
  cell function and, 315-16
Adenocarcinoma
  diesel exhaust and, 286-87
Adenoma
  diesel exhaust and, 286
Adenosine
  bioavailability of, 322-24
  calcium channels and, 352
  cell function and, 315-16
  cellular energy and, 334
  gastrointestinal system and, 333
  immune system and, 333
  ion fluxes and, 325
  neurotransmitter release and, 325-26
  phosphatidylinositol and, 325
  pulmonary system and, 332-33
  respiration and, 334
  sedative effects of, 316
  uptake of, 334
Adenosine diphosphate
  metabolism regulation and, 261
Adenosine monophosphate
  extracellular adenosine and, 323
Adenosine receptors, 317-21
  cardiovascular system and, 331-32
  central nervous system and, 328-31
  cyclic AMP and, 324-25
  kidneys and, 332
  therapeutic targeting of, 335
Adenosine recognition sites, 327-28
Adenosine triphosphate
  extracellular adenosine and, 323
  sedative effects of, 316
Adenosine triphosphate receptors, 321-22
S-Adenosylhomocysteine
  cardiac adenosine and, 323
Adenylate cyclase
  adenosine and, 316-17
  adrenergic receptors and, 216, 225
  pertussis toxin and, 324
Adenylate kinase
  ATP-binding site of, 205
Adenylyl cyclase, 371-80
  adrenergic receptors and, 374-75
  G-proteins and, 372-74
  hormone-sensitive, 379-80
  yeast, 378-79
Adrenergic receptor
  adenylyl cyclase and, 374-75
  G-proteins and, 376-78
  subtypes of, 216
Adrenergic receptor metabolism, 215-31
  in vitro studies of, 221-26
  in vivo studies of, 226-30
  kinetic analysis of, 219-20
  measurement of, 217-18
Adriamycin
  cardiac toxicity of
    carnitine and, 271
Adult respiratory distress syndrome
  platelet-activating factor and, 246-47
Adverse drug reactions, 71-72, 76-78
Affective disorders
  muscarinic supersensitivity in, 148
Aflatoxin
  immunotoxicity of, 38-39
Alcohol
  dialyzability of, 177
  poisoning by, 169
Alcohol dehydrogenase
  chloral hydrate metabolism and, 182
  ethylene glycol metabolism and, 181
  glycol ethers and, 412
  structure of, 195
Alcoholism
  REM latency and, 147
Allergic reactions
  gold and, 32
  platinum complexes and, 32
Aluminum
  extracorporeal removal of, 186
Alveolar gas exchange
  diesel exhaust and, 288
Amanita phalloides
  poisoning by, 188
Amanita verna
  poisoning by, 188

Amantadine
Parkinson's disease and, 120
Amines
aromatic
immune system and, 35
Aminophylline
digoxin and, 81
paradoxical ventilatory response and, 334
p-Aminosalicylic acid
tuberculosis and, 431
Amiodarone
extracorporeal removal of, 185
Amitriptyline
extracorporeal removal of, 184
long-term levodopa syndrome and, 118
volume of distribution of, 172
Analgesia
adenosine and, 330
Analgesic agents
extracorporeal removal of, 183-84
overdose of, 169
Anaphylactic shock
platelet-activating factor and, 246
Anaphylaxis
cardiac
platelet-activating factor and, 246
immunoglobulin E
platelet-activating factor and, 237
leukotrienes and, 304
Anemia
benzene and, 37-38
Angina
calcium channel blockers and, 347
carnitine and, 269
nitroplasters and, 433
Angiotensin-converting enzyme inhibitors of, 198, 201
Animal welfare
research and, 429-30
Anorexia nervosa
REM latency and, 147
Anthracenes
diesel exhaust and, 281
Antiarrhythmic agents
extracorporeal removal of, 185
overdose of, 169
Antiasthmatic agents
adenosine antagonists as, 335
Antibodies
adrenergic receptors and, 217
production of
heavy metals and, 33
Anticholinergic agents
dystonic syndromes and, 125
Parkinson's disease and, 119-20
Anticonvulsant agents
extracorporeal removal of, 184
Antidepressant agents
adenosine and, 330-31
adrenergic receptors and, 229
computer modeling of, 204
extracorporeal removal of, 184
Antidiarrheal agents
ligand binding and, 355
Antiepileptic agents
overdose of, 169
Antihistamine agents
Parkinson's disease and, 119-20
Antihypertensive agents
adenosine agonists as, 335
extracorporeal removal of, 185
Antimicrobial agents
extracorporeal removal of, 186
Antimony
extracorporeal removal of, 186
Antineoplastic agents
extracorporeal removal of, 186
Antipsychotic agents
adenosine agonists as, 335
Antistress agents
adenosine antagonists as, 335
Antitumor agents
binding of, 196
Anxiety
adenosine and, 329-30
Aplastic anemia
benzene exposure and, 24, 38, 400, 406
Aplisiatoxin
tumor-promoting activity of, 203-4
Apomorphine
levodopa and, 117
Parkinson's disease and, 122
Arachidonate
cyclooxygenase metabolites of
shock and, 305, 309
Arachidonic acid
adrenergic receptors and, 216
Arachidonic acid-lipoxygenase pathway
benzidine and, 35
Arecoline
Huntington's disease and, 126
REM sleep and, 144
Aricidin A
structure of, 205
Aromatic amines
immune system and, 35
Aromatic hydrocarbons
immune function and, 29-32
polycyclic
diesel exhaust and, 280-81
Arrhythmias
acetyl carnitine and, 269
calcium channel blockers and, 347
xanthines and, 332
Arsenic
extracorporeal removal of, 187
Asbestos
pulmonary disease and, 39-40
Asbestosis, 39-40
Ascorbate
benzene metabolism and, 405
Aspartate
adenosine and, 325
Aspartyl proteases
renin inhibitors and, 198
Aspergillus
ochratoxins and, 38
Aspirin
myocardial infarction and, 80
platelet-activating factor and, 240
Reye's syndrome and, 265
Asthma
calcium channel blockers and, 347
platelet-activating factor and, 246
Atenolol
extracorporeal removal of, 185
Atherosclerosis
calcium channel blockers and, 347
Atonia
acetylcholine and, 142-43
Atropine
cholinergic desynchronization and, 140
ponto-geniculo-occipital waves and, 141
REM sleep and, 144
vasoactive intestinal peptide and, 57
Atrotoxin
calcium channels and, 352
Attention-deficit disorder
REM latency and, 147
Autoantibodies
asbestosis and, 40
silicosis and, 40
Autoimmune disease
silicosis and, 40

Autoimmunity
heavy metals and, 34
Autonomic agents
overdose of, 169
Autoradiography
cholinergic receptors and, 138

B

Baclofen
long-term levodopa syndrome and, 118
Barbiturates
extracorporeal removal of, 181-82
overdose of, 169
Barium
extracorporeal removal of, 186
Basophils
adenosine and, 333
B cell–differentiation factors, 27
B cell–growth factor II, 27
B cells
activation of
benzene derivatives and, 37
development of, 26-27
polycyclic aromatic hydrocarbons and, 29
2,3,7,8-tetrachlorodibenzo-*p*-dioxin and, 31-32
B cell–stimulatory factor, 27
Benoxaprofen
adverse drug reactions and, 71
Benserazide
levodopa therapy and, 114-15
Benzene, 24
immunotoxicity of, 37-38
metabolism of, 400-6
metabolites of
binding of, 404-6
toxicity of, 406-9
Benzidine
immunosuppression and, 35
Benzopyrene
B cells and, 29
carcinogenicity of, 285
mutagenicity of, 282
tissue retention of, 284-85
Benzodiazepine receptor
isobutylmethylxanthine and, 329
pyrazoloquinoline and, 328
Benzodiazepines
anxiolytic activity of, 329-30
calcium channels and, 351
extracorporeal removal of, 184
Benzothiazepines
binding sites for, 349
Benztropine
dystonic syndromes and, 125
Huntington's disease and, 126
Parkinson's disease and, 119
Berylliosis, 40
Beryllium
immunotoxicity of, 40
Bethanechol
cholinergic desynchronization and, 140
Bioassay
bioequivalence and, 392-94
mixtures and, 394-96
multivariate, 391-92
statistical methods for, 385-96
univariate, 386-91
Biperiden HCl
Parkinson's disease and, 119
Biphenyls
diesel exhaust and, 281
Bladder cancer
diesel exhaust exposure and, 290-91
Blood-brain barrier
peripheral decarboxylase inhibitors and, 114
Blood dyscrasias
benzene exposure and, 400
Bone marrow
benzene metabolism and, 400
glycol ethers and, 413
Bone-marrow hypoplasia
benzene and, 37
Bornaprine HCl
Parkinson's disease and, 119
Boston Collaborative Drug Surveillance Program, 77-78
Bovine follicular inhibin, 12-14
Bovine inhibin, 10
Bradycardia
adenosine and, 316
Bretylium
extracorporeal removal of, 185
Bromobenzene
hepatotoxicity of, 418
p-Bromobenzyloxyacetic acid
binding site of, 195
Bromocriptine
dystonic syndromes and, 124
Parkinson's disease and, 121-22
Bronchoalveolar adenoma
diesel exhaust and, 286
Bronchoconstriction
platelet-activating factor and, 239-41, 247
Bronchodilation
theophylline and, 332-33
Brotizolam
platelet-activating factor and, 243-44
Buprenorphine, 431

C

Cadmium
antibody production and, 33
extracorporeal removal of, 186
immune system and, 32-33
Caffeine
anxiety and, 329-30
convulsant activity of, 330
cyclic AMP and, 316
dopamine metabolism and, 326
self-destructive behavior and, 331
stress-related events and, 333
Calcium
diesel exhaust particles and, 280
inositol triphosphate and, 27
Calcium channel blockers
platelet-activating factor and, 243-44
Calcium channel ligands, 347-61
binding sites for, 352-56
regulation of, 358-61
structure-function relationships of, 349-52
tissue selectivity of, 356-58
Cancer
polychlorinated biphenyls and, 94, 98
respiratory tract
diesel exhaust particles and, 285-88
Captain
immunotoxicity of, 36
Carbachol
cataplexy and, 142
cholinergic desynchronization and, 140
ponto-geniculo-occipital waves and, 141
Carbamazepine
adenosine receptors and, 330, 334
extracorporeal removal of, 184
Carbidopa
levodopa therapy and, 114-15
Carbohydrate oxidation
regulation of, 261
β-Carbolines, 329
Carbon
diesel exhaust particles and, 280
Carbonic anhydrase
structure of, 195

sulfonamide inhibitors of, 195
Carbon monoxide
poisoning by, 169
Carbon tetrachloride
hepatotoxicity of, 415-18
Carboxypeptidase
structure of, 195
Carcinogenesis
benzidine and, 35
benzopyrene and, 285
dimethylnitrosamine and, 39
polycyclic aromatic hydrocarbons and, 29
polyhalogenated aromatic hydrocarbons and, 30
Carcinoma
diesel exhaust and, 287
polychlorinated biphenyls and, 98
Cardiac anaphylaxis
platelet-activating factor and, 246
Cardiac arrhythmias
See Arrhythmias
Cardiac glycosides
extracorporeal removal of, 184-85
Cardiomyopathy
calcium channel blockers and, 347
carnitine deficiency and, 263-64
Cardiotonic agents
adenosine antagonists as, 335
Cardiovascular agents
extracorporeal removal of, 184-85
overdose of, 169
Cardiovascular disease
calcium channel blockers and, 347
Carnitine
biochemical role of, 257-61
heart and, 269-71
hemodialysis and, 268-69
neonatal, 266-67
neuropharmacology of, 267-68
pharmacology of, 257-72
Carnitine deficiency syndromes, 261-67
Case-control studies, 73
Case reports, 72
Case series, 72
Cataplexy
narcolepsy and, 149
Catecholamines
adrenergic receptors and, 215-16, 229
calcium channels and, 352
REM sleep and, 143
Cell-mediated immunity
asbestosis and, 40
benzene and, 409
benzidine and, 35
diethylstilbestrol and, 24, 36
dimethylnitrosamine and, 39
lead and, 32-33
lymphokines and, 28
polycyclic aromatic hydrocarbons and, 29
silicosis and, 40
Central nervous system
adenosine receptors and, 328-31
carnitine and, 267-68
Central nervous system agents
extracorporeal removal of, 177-84
Chelation therapy
aluminum intoxication and, 186
iron intoxication and, 187
lead intoxication and, 187
mercury intoxication and, 187
methylmercury intoxication and, 187-88
Chloracne
polybrominated biphenyls and, 89
polychlorinated biphenyls and, 91-92, 96, 99
Chloral hydrate
extracorporeal removal of, 182
Chloramphenicol
extracorporeal removal of, 186
Chlordane
immunotoxicity of, 36
Chlordecone
immunotoxicity of, 35
Chlordiazepoxide
extracorporeal removal of, 184
Chlorinated dibenzodioxins, 88
2-Chloroadenosine
adenosine receptors and, 318
Chlorphenoxamine
Parkinson's disease and, 119-20
Cholera toxin
GTP binding site for, 372
transducin and, 376
Cholesterol
carnitine and, 262
Choline
carnitine transport and, 260
Choline acetylase
Huntington's disease and, 126
Choline-acetyltransferase
labeling of, 138
Cholinergic neurons
acetylcholinesterase and, 138-39
Cholinergic receptors
autoradiography and, 138
phenoxybenzamine and, 221
Cholinergic system
organization of, 138-39
Chromium
diesel exhaust particles and, 280
extracorporeal removal of, 186
Chromosome aberrations
diesel exhaust particles and, 282
Chronic pulmonary granulomatosis
beryllium and, 40
Chymotrypsin
structure of, 195
Cigarette smoking
bladder cancer and, 291
lung cancer and, 290
Citrate synthetase
acetyl-CoA and, 259
Clioquinol
adverse drug reactions and, 71
Clofibrate
volume of distribution of, 171
Clonazepam
Parkinson's disease and, 123
Clonidine
adrenergic receptors and, 221
Gilles de la Tourette's syndrome and, 128
quasi-morphine withdrawal syndrome and, 330
withdrawal from, 358-59
Coal dust
lung cancer and, 288
Cocaine
overdose of, 169
Coenzyme A
carnitine and, 257-61
Cohort studies, 73
Cold urticaria
platelet-activating factor and, 247
Commission on Professional and Hospital Activities' Professional Activities Survey, 78
Complement
benzene exposure and, 38
Computerized On-Line Medicaid Pharmaceutical Analysis and Surveillance System, 79
Computer modeling
drug design and, 193-208
Concanavalin A
phosphatidylinositol and, 27

Congestive heart failure
calcium channel blockers and, 347
Conotoxins
calcium channels and, 352
Copper
extracorporeal removal of, 187
Coprolalia
Gilles de la Tourette's syndrome and, 127
Coronary blood flow
adenosine and, 331
Corticosteroids
interleukin-1 and, 26
Cranial dystonia
drugs affecting, 124-25
Cyclic AMP
adenosine and, 316-17, 323
adenosine receptors and, 324-25
adenylyl cyclase and, 371
adrenergic receptors and, 216, 225-26
Cycloheximide
adrenergic receptors and, 222-23, 226
Cyclohexyladenosine
adenosine receptors and, 317
Cyclopentenopiperazinylindolinone
platelet-activating factor and, 244
Cyclopentyladenosine
adenosine receptors and, 317
8-Cyclopentyltheophylline
adenosine receptors and, 328
Cycrimine HCl
Parkinson's disease and, 119
L-Cystine
methylmercury poisoning and, 187-88
Cytochrome P-450
benzene metabolism and, 400-3
Cytotoxic T cells
DNA synthesis in, 27
functions of, 27
polycyclic aromatic hydrocarbons and, 29
2,3,7,8-tetrachlorodibenzo-*p*-dioxin and, 31
O,O,S-trimethylphosphorothioate and, 37

D

Daunomycin
intercalation and, 196
DDT
immunotoxicity of, 35, 36
Death cap
poisoning by, 188
Deferoxamine
aluminum intoxication and, 186
iron intoxication and, 187
Delayed hypersensitivity
asbestosis and, 39
berylliosis and, 40
lead exposure and, 33
Dementia
levodopa syndrome and, 116
Demeton-*S*-methyl sulfoxide
extracorporeal removal of, 188
Deoxycoformycin
sleep and, 329
Deoxyhemoglobin S, 195
L-Deprenyl
Parkinson's disease and, 123
Depression
adenosine and, 330-31
REM latency and, 147-48
Dermatitis
beryllium and, 40
Destroying angel
poisoning by, 188
Dexamethasone
carnitine and, 262
Diabetes
carnitine and, 270
Diacylglycerol
conformation of, 202
protein kinase C and, 27, 204
Dialkyltins
humoral immunity and, 34
Dialysis
drug clearance and, 172, 173-75
drug overdose and, 170
pharmacokinetics of, 170-73
4,4-Diaminobiphenyl
See Benzidine
Diazepam
carbamazepine and, 330
extracorporeal removal of, 184
Dibenzofurans, 24, 30, 88, 99
Diesel exhaust
health effects of, 279-95
Diesel exhaust particles
bioassays of, 281-83
chemical composition of, 280-81
epidemiology of, 289-92
inhaled
disposition of, 283-84
lung cancer and, 289-94
organic constituents of
disposition of, 284-85
respiratory tract cancer and, 285-88
surface area of, 280
Diethylene glycol
adverse drug reactions and, 71
Diethylnitrosamine
carcinogenicity of, 285
Diethylstilbestrol, 24
immunotoxicity of, 35-36
Digitoxin
extracorporeal removal of, 184-85
Digoxin
aminophylline and, 81
extracorporeal removal of, 184-85
overdose of, 169
volume of distribution of, 171
Dihydroalprenolol
adrenergic receptors and, 223
Dihydrofolate reductase
analogs for, 194
structure of, 195
1,4-Dihydropyridines, 347-48
antagonists and, 350
binding sites for, 349, 354-55, 360
conotoxins and, 352
interactions of, 357
membrane affinities for, 352
receptors for, 353
t-tubule channel complex for, 356
DL-threo-Dihydroxyphenylserine
Parkinson's disease and, 123
Di-isopropanol-nitrosamine
carcinogenicity of, 286
Diltiazem, 347-48
binding sites for, 355
conotoxins and, 352
platelet-activating factor and, 244
withdrawal from, 359
Dimercaprol
arsenic poisoning and, 187
mercury intoxication and, 187
Dimethoate
extracorporeal removal of, 188
7,12-Dimethylbenzanthracene
B cells and, 29
Dimethylnitrosamine
immunotoxicity of, 39
Di-*n*-butyltindichloride
immunosuppression and, 34
Di-*n*-octyltindichloride
immunosuppression and, 34
Dioxin, 24, 30
Diphenhydramine
Parkinson's disease and, 119
Diphenoxylate
addiction and, 431
2,3-Diphosphoglycerate
structure of, 194

Diphtheria
cardiac carnitine and, 264
Dipyridamole
adenosine transport and, 324
benzodiazepine receptor and, 329
Diquat
extracorporeal removal of, 188
Disopyramide
extracorporeal removal of, 185
Divinylether
anesthesia and, 431-32
DNA alkylation
aflatoxins and, 39
DNA synthesis
benzene and, 403-4
cytotoxic T cells and, 27
interleukin-1 and, 26
Dopamine
adenosine and, 326, 331
Dopamine-β-hydroxylase
cotransmission of, 61-62
Dopaminergic receptors
phenoxybenzamine and, 221
Drug design
computer-aided, 193-208
Drug discovery, 430-32
Drug effects
studies of, 80-81
Drug interactions
studies of, 81
Drug overdose, 169
dialysis and hemoperfusion and, 170
Drug reactions
adverse, 71-72, 76-78
Drugs
dialyzability of, 173-75
extracorporeal removal of, 169-88
movement disorders and, 113-29
Drug safety
establishment of, 74-76
Drug utilization review, 82
Duchenne muscular dystrophy
carnitine levels in, 266
Dyskinesia
levodopa therapy and, 116-17
Dysmenorrhea
calcium channel blockers and, 347
Dystonic syndromes
drugs affecting, 124-26

E

Echophenomena
Gilles de la Tourette's syndrome and, 127
Eicosanoids
shock and, 302-3, 309
Electroconvulsive therapy
adenosine receptors and, 331
Endotoxemia
leukotriene antagonists and, 305
prostaglandins and, 302
thromboxane A_2 and, 304
Endotoxic shock
eicosanoids and, 303
lipoxygenase pathway inhibitors and, 305
prostaglandins and, 302
thromboxane A_2 and, 303
Endotoxin
platelet-activating factor and, 246
Enkephalin
analogs for, 204
backbone conformation of, 206
cotransmission of, 58
Environmental agents
mononuclear phagocytes and, 25
Eosinophils
diesel exhaust particles in, 288
platelet-activating factor and, 239
Epidemiology
study design in, 72-74
Epidermal growth factor receptor
kinetic analysis of, 219
2,3,7,8-tetrachlorodibenzo-*p*-dioxin and, 32
Epilepsy
adenosine and, 330
Epinephrine
adrenergic receptors and, 216
Ergot derivatives
dystonic syndromes and, 124
Parkinson's disease and, 121-22
Erythrocytes
glycol ethers and, 413
Erythrohydroxynonyladenine
sleep and, 329
Erythroid cells
glycol ethers and, 413
Escherichia coli
cAMP receptor protein of, 205
RecA protein of, 199
Estradiol
immunotoxicity of, 35
Estrogens
immunotoxicity of, 35-36
Ethanol
methanol intoxication and, 181
Ethanolamine
carnitine and, 267
Ethchlorvynol
extracorporeal removal of, 182
metabolic clearance of, 172
Ethopropazine
dystonic syndromes and, 125
Parkinson's disease and, 119
Ethosuximide
extracorporeal removal of, 184
N-Ethoxycarbonyl-2-ethoxy-1, 2-dihydroquinoline
adrenergic receptors and, 221
Ethylene glycol
dialyzability of, 177, 181
Ethylene glycol monobutyl ether
hematological effects of, 412-13
Ethylene glycol monoethyl ether
hematological effects of, 413
N-Ethylmaleimide
adenosine receptors and, 320
Eukaryotic cells
trichothecenes and, 39
Experimental studies, 73-74

F

Fatty acid metabolism
carnitine and, 261
Felodipine, 347
Fenfluramine
Huntington's disease and, 127
Fenitrothion
immunotoxicity of, 37
Fibers
mononuclear phagocytes and, 25
Fibroblasts
silicosis and, 40-41
Flecainide
extracorporeal removal of, 185
Fluorenes
diesel exhaust and, 281
Fluoride
extracorporeal removal of, 187
Fluphenazine
Gilles de la Tourette's syndrome and, 128
Huntington's disease and, 127
Flurazepam
extracorporeal removal of, 184
Focal dystonia
drugs affecting, 124-25
Folate
methanol intoxication and, 181

Follicle-stimulating hormone
inhibin and, 1, 16-17
inhibinlike peptide and, 4
Follicle-stimulating hormone-releasing hormone, 16-17
Follitropin
α-inhibin-92 and, 6

G

Gallopamil, 347
Gamma-aminobutyric acid
adenosine and, 326
inhibitors of, 203
Gamma-aminobutyric acid receptor
phenoxybenzamine and, 221
Ganglia
sympathetic
cotransmission in, 54-55
Gases
mononuclear phagocytes and, 25
Gilles de la Tourette's syndrome
drugs affecting, 127-28
Glomerulonephritis
mercury and, 34
platelet-activating factor and, 246
Glucagon
antihypertensive agent overdose and, 185
Glucocorticoids
carnitine and, 262
platelet-activating factor and, 240, 243
Glucose metabolism
interleukin-1 and, 26
organotins and, 35
Glutamate
adenosine and, 325
Glutamic acid decarboxylase
Huntington's disease and, 126
γ-Glutamyltranspeptidase
polychlorinated biphenyls and, 96
Glutathione
analogs for, 205
Glutethimide
extracorporeal removal of, 182
Glyceryltrinitrate
angina and, 433
Glycol ethers, 409-15
developmental toxicity of, 413-15
hematological effects of, 412-13
male reproductive system and, 410-12
Glyoxalase I
glutathione analogs and, 205
Gold
immune system and, 32
Gold salts
nephrotoxicity of, 32
Gonads
inhibin and, 8
G-proteins, 372-78
adrenergic receptors and, 376-78
Granulocytopenia
benzene and, 37
Granulomatosis
beryllium and, 40

H

Hallucinosis
levodopa therapy and, 118
Haloperidol
dystonic syndromes and, 125
Gilles de la Tourette's syndrome and, 128
Huntington's disease and, 127
Halothane
jaundice and, 77
Heart
carnitine and, 260, 269-71
cotransmission in, 55-56
Heart contractility
adenosine and, 331
Heavy metals
immune system and, 32-34
toxicity of, 159
Hematopoiesis
benzene and, 406-9
2,3,7,8-tetrachlorodibenzo-*p*-dioxin and, 31
Hemicholinium-3
postganglionic nerve stimulation and, 56
Hemoconcentration
platelet-activating factor and, 240-41
Hemodialysis
carnitine and, 268-69
drug overdose and, 177-88
protein binding and, 171
Hemoglobin
structure of, 195
Hemoglobinuria
glycol ethers and, 412
Hemolytic anemia
glycol ethers and, 412
Hemoperfusion
drug clearance and, 172, 175-76
drug overdose and, 170, 177-88
pharmacokinetics of, 170-73
protein binding and, 171
Hemorrhagic shock
prostaglandins and, 302
thromboxane A_2 and, 303
Hepatitis
methyldopa and, 77
Hepatocytes
aflatoxins and, 39
Hepatoma
benzidine and, 35
Hepatotoxicity
carbon tetrachloride, 415-18
solvent
calcium ion homeostasis and, 418-19
Herbicides
extracorporeal removal of, 188
poisoning by, 169
Histamine
adenosine and, 325, 333
calcium channels and, 352
HLA antigen DR2
narcolepsy and, 149
Hodgkin's disease
adenosine and, 333
Homeostasis
carnitine and, 261
Hormones
transmembrane signaling and, 27
Host resistance
heavy metals and, 33
lead exposure and, 32
polycyclic aromatic hydrocarbons and, 29
2,3,7,8-tetrachlorodibenzo-*p*-dioxin and, 30
Human milk
polybrominated biphenyls in, 105
polychlorinated biphenyls in, 90-91, 97
Humoral immunity
dialkyltins and, 34
dimethylnitrosamine and, 39
lead and, 32-33
platinum complexes and, 32
polycyclic aromatic hydrocarbons and, 29
silicosis and, 40
Huntington's disease
drugs affecting, 126-27
Hydrocarbons
polycyclic aromatic, 29-30
diesel exhaust and, 280-81
polyhalogenated aromatic, 30-32
Hydrogen
diesel exhaust particles and, 280
Hydroquinone
immunotoxicity of, 37
Hydroquinones
benzene metabolism and, 400

6-Hydroxydopamine
cardiac β-adrenoceptors and, 359
neuropeptide Y and, 58
Hyperacute organ transplant rejection
platelet-activating factor and, 247
Hypercortisolemia
REM latency and, 147-48
Hypersensitivity
delayed
asbestosis and, 39
berylliosis and, 40
lead exposure and, 33
Hypertension
calcium channel blockers and, 347
Hypnotic agents
adenosine agonists as, 335
extracorporeal removal of, 181-83
Hypocalcemia
ethylene glycol and, 181
Hypoglycemia
carnitine deficiency and, 264
Hypoglycin
vomiting sickness and, 265
Hypoketonemia
carnitine deficiency and, 264
Hypotension
platelet-activating factor and, 239-40
Hypothalamo-pituitary-gonadal axis
inhibin and, 1, 18
Hypothalamus
inhibin and, 8, 16
Hypoxanthine-guanine phosphoribosyltransferase
Lesch-Nyhan syndrome and, 331
Hypoxia
carbon tetrachloride-induced hepatotoxicity and, 416

I

Imidazopyrimidines
adenosine receptors and, 315
Imipramine
extracorporeal removal of, 184
Immune competence
adenosine agonists and, 335
Immune complexes
interleukin-1 synthesis and, 26
Immune system
aromatic amines and, 35
benzene and, 37-38
dimethylnitrosamine and, 39
organometals and, 34-35
pesticides and, 36-37
pharmacology of, 24-28
pulmonary irritants and, 39-41
xenobiotics and, 28-41
Immunoglobulin E anaphylaxis
platelet-activating factor and, 237
Immunoglobulin M
B cell growth factors and, 27
Immunoglobulins
asbestosis and, 40
benzene exposure and, 38
membrane-associated
B cells and, 26-27
silicosis and, 40
Immunosuppression
benzene and, 409
benzidine and, 35
chlordane and, 36
diethylstilbestrol and, 36
heavy metals and, 32-34
ochratoxins and, 38-39
polycyclic aromatic hydrocarbons and, 29
2,3,7,8-tetrachlorodibenzo-*p*-dioxin and, 30-32
Immunotoxicity
chemically induced, 23-41
Immunotoxic xenobiotics, 28-41
Indomethacin
benzene toxicity and, 407
platelet-activating factor and, 240
Inflammation
monocytes and, 25
platelet-activating factor and, 246
Inhibin, 1-18
bioassay of, 2-4
follicular fluid, 10-14
seminal fluid, 4-10
α-Inhibin-92, 5-9
β-Inhibin, 9-10
Inhibinlike peptide, 4-5
Inositol triphosphate
calcium activation and, 27
Insulin receptor
kinetic analysis of, 219
γ-Interferon
interleukin-1 synthesis and, 26
Interleukin-1
B cells and, 27
lymphoblasts and, 27
mononuclear phagocytes and, 26
Interleukin-2
estrogens and, 36
formation of, 26
T helper cells and, 27
Intestinal spasm
calcium channel blockers and, 347
Iodocyanopindolol
adrenergic receptors and, 223
Iodohydroxypindolol
adrenergic receptors and, 223
Iodopindolol
adrenergic receptors and, 223
Iron
diesel exhaust particles and, 280
extracorporeal removal of, 187
Ischemic bowel necrosis
platelet-activating factor and, 247
Isobole, 394
Isobologram, 394
Isobutylmethylxanthine
benzodiazepine receptor and, 329
Isoniazid
Huntington's disease and, 126-27
tuberculosis and, 431
Isopropanol
dialyzability of, 177
Isoproterenol
adrenergic receptors and, 225

J

Jaundice
halothane and, 77

K

Kadsurenone
platelet-activating factor and, 240, 244
Kainate
seizures and, 330
Keratinocytes
2,3,7,8-tetrachlorodibenzo-*p*-dioxin and, 32
Kidney
carnitine reabsorption in, 261
Kidney disease
drug-protein binding and, 173
end-stage
digoxin and, 171

L

Labyrinthine disorders
calcium channel blockers and, 347
Lactic acidosis
ethylene glycol and, 181
Lead
antibody production and, 33
extracorporeal removal of, 187
immune system and, 32-33

toxicity of, 159
β-Leptinotarsin-h
calcium channels and, 352
Lergotrile mesylate
Parkinson's disease and, 121
Lesch-Nyhan syndrome, 331
Leukemia
benzene and, 24
Leukocytes
polymorphonuclear
interleukin-1 and, 26
Leukopenia
benzene and, 37-38
platelet-activating factor and, 246
trichothecenes and, 39
Leukotrienes
shock and, 304-5
Levodopa
dystonic syndromes and, 124-26
melanoma and, 118-19
Parkinson's disease and, 114-19
withdrawal from, 118
Levodopa syndrome, 116-18
Lidocaine
extracorporeal removal of, 185
Limb girdle dystrophy
long-chain acyl CoA levels in, 266
Lipid oxidation
regulation of, 261
Lipid peroxidation
carbon tetrachloride-induced, 415-19
Lipids
vasoactive
shock and, 301-10
Lipopolysaccharide
interleukin-1 synthesis and, 26
Lipoxygenase inhibitors
shock and, 305
Listeria monocytogenes
lead exposure and, 32
Lisuride
dystonic syndromes and, 124
Parkinson's disease and, 121-22
Lithium
extracorporeal removal of, 184
Huntington's disease and, 127
volume of distribution of, 171
Liver
carnitine transport and, 260
polychlorinated biphenyls and, 96-97
Long-chain fatty acid oxidation
carnitine and, 257-60
Lorazepam
extracorporeal removal of, 184
Lung cancer
diesel exhaust and, 285-94
Luteinizing hormone-releasing hormone
cotransmission of, 54-55
inhibin and, 2-4, 16-17
Lymphoblasts
interleukin-1 and, 27
Lymphocytes
activation of
gold and, 32
adenosine and, 333
beryllium and, 40
interleukin-1 and, 26
polycyclic aromatic hydrocarbons and, 29
proliferation of
platinum complexes and, 32
2,3,7,8-tetrachlorodibenzo-*p*-dioxin and, 31
thiols and, 33-34
trichothecenes and, 39
See also B cells; T cells
Lymphocytopenia
benzene exposure and, 37, 400, 408
O,O,S-trimethylphosphorothioate and, 37
Lymphoid cells
metal-induced injury to, 33-34
Lymphokines
cell-mediated immunity and, 28
Lymphoma
benzidine and, 35
Lymphopoiesis
benzene and, 408-9
Lysosomal enzymes
interleukin-1 and, 26

M

Macrophages
asbestosis and, 40
benzene toxicity and, 408
beryllium and, 40
development of, 25-26
diesel exhaust particles and, 284, 288
heavy metals and, 32-33
platinum complexes and, 32
silicosis and, 40-41
trichothecenes and, 39
O,O,S-trimethylphosphorothioate, 37
Magnesium
extracorporeal removal of, 186
Maitotoxin
calcium channels and, 352
Malathion
immunotoxicity of, 37
Manganese
extracorporeal removal of, 186
Mast cells
benzene and, 406
Meige's syndrome
drugs affecting, 124-25
Melanoma
levodopa and, 118-19
polychlorinated biphenyls and, 98
Menadione
heptatotoxicity of, 418
Mepacrine
platelet-activating factor and, 240
Meprobamate
anxiolytic activity of, 330
extracorporeal removal of, 183
Mercaptoproprionic acid
seizures and, 330
Mercury
antibody production and, 33
extracorporeal removal of, 187
immune system and, 32-34
Mesothelioma
asbestos and, 39
Mesulergine
Parkinson's disease and, 121
Metabolic acidosis
methanol intoxication and, 181
Metals
extracorporeal removal of, 186-88
poisoning by, 169
See also Heavy metals
Methanol
dialyzability of, 177-81
volume of distribution of, 171
Methaqualone
extracorporeal removal of, 183
Methixene
Parkinson's disease and, 119
Methotrexate
extracorporeal removal of, 186
volume of distribution of, 171
Methyldopa
hepatitis and, 77
Methylmercury
extracorporeal removal of, 187-88
immune system and, 34
Methylparathion
immune function and, 37

Methylphenidate
Gilles de la Tourette's syndrome and, 128
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Parkinson's disease and, 123
Methyprylon
extracorporeal removal of, 182-83
Methysergide
long-term levodopa syndrome and, 118
Metoclopramide
extrapyramidal side effects of, 77
levodopa absorption and, 115
Metrazole
seizures and, 330
Mexiletine
extracorporeal removal of, 185
Mianserin
computer modeling of, 204
Microsomes
benzene metabolism and, 400-3
Microtubules
benzene metabolites and, 37-38
Migraine
calcium channel blockers and, 347
Minamata disease
methylmercury and, 34
Minerals
extracorporeal removal of, 186-88
Mitochondria
benzene metabolism and, 403
coenzyme A and, 259
Monocytes
inflammation and, 25
polycyclic aromatic hydrocarbons and, 29
Mononuclear phagocytes
development of, 25-26
interleukin-1 synthesis and, 26
Monte Carlo sampling
computer-aided drug design and, 206
Morphiceptin
analogs for, 204
Morphine analgesia
xanthines and, 330
Motor activity
adenosine and, 328-29
Movement disorders
drugs affecting, 113-29
Mushroom poisoning, 188
Mutagenicity
benzopyrene and, 282
diesel exhaust particle extracts and, 279
nitroaromatic compounds and, 280-81
Mycotoxic shock
prostaglandins and, 302
Mycotoxins
immunotoxicity of, 38-39
Myeloid cells
glycol ethers and, 413
Myelotoxicity
benzene and, 37
diethylstilbestrol and, 36
polyhalogenated aromatic hydrocarbons and, 31
Myocardial infarction
aspirin and, 80

N

Nadolol
extracorporeal removal of, 185
Nalorphine
opiate overdose and, 431
Naloxone
long-term levodopa syndrome and, 118
opiate overdose and, 431
Naphthalenes
diesel exhaust and, 281
Narcolepsy, 142
REM latency and, 147, 149
Natural killer cells
asbestosis and, 40
diethylstilbestrol and, 24, 36
Necrotizing enterocolitis
platelet-activating factor and, 246
Neoplasia
benzidine and, 35
immune dysfunction and, 24
Neostigmine
extracorporeal removal of, 188
Netropsin-B
DNA double-helix complex of, 196
Neuroleptic agents
dystonic syndromes and, 125
Gilles de la Tourette's syndrome and, 128
Huntington's disease and, 127
ligand binding and, 355
Neurons
adrenergic postganglionic cotransmission in, 58-59
cholinergic
acetylcholinesterase and, 138-39
cholinergic postganglionic cotransmission in, 56-57
cotransmission in, 51-65
sympathetic
cotransmission in, 53-54
Neuropeptides
calcium channels and, 352
Neuropeptide Y
corelease of, 60
cotransmission of, 58-59
Neurotransmitters
adenosine and, 325-26
calcium channels and, 352
cotransmission of, 51-65
transmembrane signaling and, 27
Neutropenia
platelet-activating factor and, 240
Neutrophils
interleukin-1 and, 26
platelet-activating factor and, 239
Nicardipine, 347, 357
Nicotinic acid
plasma free fatty acids and, 270
Nifedipine, 347
withdrawal from, 359
Nimoldipine, 347
Nisoldipine, 347
Nitrendipine, 347
binding sites for, 359
membrane affinities for, 352
Nitroaromatic compounds
mutagenicity of, 280-81
Nitrobenzylthioinosine
adenosine transport and, 324
Nitrogen
diesel exhaust particles and, 280
nitro plasters
angina and, 433
Nitropyrene
tissue retention of, 284-85
Nootropic agents
adenosine antagonists as, 335
Norepinephrine
adenosine and, 326
adrenergic receptors and, 216, 227-28
corelease of, 60-61
cotransmission of, 53-54, 58-59
ponto-geniculo-occipital waves and, 141
quasi-morphine withdrawal syndrome and, 330
REM sleep and, 143
serotonin and, 52
Nortriptyline
extracorporeal removal of, 184
Nuclear magnetic resonance spectroscopy
macromolecules and, 193-94

O

Obsessive-compulsive disorder
REM latency and, 147
Ochratoxin
immunotoxicity of, 38-39
Oculomucocutaneous syndrome
practolol and, 71
Opiate overdose
naloxone and, 431
Opiate receptors
phenoxybenzamine and, 221
Opiates
adenosine receptors and, 334
calcium channels and, 352
overdose of, 169
Opiate withdrawal
adenosine agonists and, 335
Oral contraceptives
thromboembolism and, 77
Organic acidemias
carnitine and, 262-63
Organochlorines
immunotoxicity of, 36
Organometals
immune system and, 34-35
Organophosphates
extracorporeal removal of, 188
immunotoxicity of, 36
Organotins
immune system and, 34-35
toxicity of, 159
Orphenadrine
Parkinson's disease and, 120
Ovaries
inhibin and, 17
Oxfenicine
fatty acid oxidation and, 270
Oxidative phosphorylation
carnitine and, 263
Oxophenarsine
syphilis and, 431
Oxotremorine
cholinergic desynchronization and, 140
Oxygen
diesel exhaust particles and, 280

P

Palmitate
carnitine and, 257
Pancytopenia
benzene exposure and, 37, 400
Papain
structure of, 195
Para-benzoquinone
immunotoxicity of, 37
Paraquat
extracorporeal removal of, 188
Parasites
inflammatory macrophages and, 26
Paraxon
extracorporeal removal of, 188
Parkinson's disease
amantadine and, 120
anticholinergic agents and, 119-20
antihistamine agents and, 119-20
ergot derivatives and, 121-22
levodopa and, 114-19
Particulates
mononuclear phagocytes and, 25
Parturition
platelet-activating factor and, 247
Penicillamine
arsenic poisoning and, 187
Wilson's disease and, 128-29
Penicillium
ochratoxins and, 38
2,3,4,7,8-Pentachlorodibenzofuran, 99
Pergolide
Parkinson's disease and, 121-22
Peripheral decarboxylase inhibitor
levodopa therapy and, 114-15
Parkinson's disease and, 122
Peritoneal dialysis
drug clearance and, 175
Pertussis toxin
adenylate cyclase and, 324
adenylyl cyclase and, 374
GTP binding site for, 372
transducin and, 376
Pesticides
extracorporeal removal of, 188
immunotoxicity of, 36-37
Phagocytes
mononuclear
development of, 25-26
interleukin-1 synthesis and, 26
Phagocytosis
lead and, 32
responsive macrophages and, 26
Pharmacoepidemiology, 71-84
current systems in, 76-79
methodology of, 74-76
opportunities in, 79-82
problems in, 82-84
study design in, 72-74
Phenethanolamines
binding sites for, 203
Phenobarbital
hemodialysis and, 181
Phenoxybenzamine
adrenergic receptors and, 221-23
Phenoxypropranolamines
binding sites for, 203
Phenylalanine
ochratoxins and, 38-39
Phenylalkylamines, 347
binding sites for, 349
2-Phenylaminoadenosine
adenosine receptors and, 318
Phenylephrine
adrenergic receptors and, 227
Phenylisopropyladenosine
adenosine receptors and, 317
8-Phenyltheophylline
adenosine and, 316
Phenytoin
dialyzability of, 173
extracorporeal removal of, 184
volume of distribution of, 171
Phocomelia
thalidomide and, 71
Phorbol esters
tumor-promoting activity of, 203-4
Phorbol myristic acetate
interleukin-1 synthesis and, 26
Phosphatidylinositol
adenosine and, 325
adrenergic receptors and, 216
hydrolysis of
phospholipase C and, 27
Phospholipase C
phosphatidylinositol hydrolysis and, 27
Phospholipid metabolism
transmembrane signaling and, 27
Phosphorus
diesel exhaust particles and, 280
Physostigmine
depression and, 148
Huntington's disease and, 126
ponto-geniculo-occipital waves and, 141
REM sleep and, 140, 144
Phytohemagglutinin
phosphatidylinositol and, 27
Picrotoxin
seizures and, 330
Pimozide
dystonic syndromes and, 125
Pineal gland
inhibin and, 8

Pituitary gland
inhibin and, 1, 8, 16-17
Plasminogen activator
responsive macrophages and, 26
Platelet-activating factor
analogs for, 241-44
pharmacology of, 238-39
shock and, 305-9
Platelet-activating factor antagonists, 237-47
clinical indications for, 246-47
discovery of, 240-41
Platelet aggregation
thromboxane A_2 and, 303
Platinum
immune system and, 32
Pneumonia
benzene exposure and, 38
Pneumonitis
beryllium and, 40
Poisons
extracorporeal removal of, 169-88
Polybrominated biphenyls, 24, 30, 103-6
commercial production of, 88-89
human exposure to, 89-91
Polychlorinated biphenyls, 24, 30, 91-103
commercial production of, 87-88
human exposure to, 89-91
immunological effects of, 31
toxic effects of, 93-94
Polychlorinated dibenzofurans, 88, 99
Polycyclic aromatic hydrocarbons
diesel exhaust and, 280-81
immune function and, 29-30
Polyhalogenated aromatic hydrocarbons
immune function and, 30-32
Polymer materials
protocol tests for, 163-65
safety evaluation of, 157-66
screening tests for, 158-63
Polymorphonuclear leukocytes
diesel exhaust particles and, 288
interleukin-1 and, 26
Polyvinyl chloride
disposal of, 157
Pontine reticular formation
REM sleep and, 140, 143-46
Porcine follicular inhibin, 10-12
Practolol
adverse drug reactions and, 71
Prazosin
adrenergic receptors and, 221, 228
syncope and, 80
Prealbumin
thyroid hormones and, 197
Prednisone
carnitine and, 262
Premature labor
calcium channel blockers and, 347
Primidone
extracorporeal removal of, 184
Procainamide
extracorporeal removal of, 185
Procyclidine HCl
Parkinson's disease and, 119
Progenitor cells
benzene and, 406-7
Promonocytes
development of, 25
Propentofylline
adenosine receptors and, 328
Propionate
oxidative phosphorylation and, 263
Propionic acidemia
carnitine and, 263
Propranolol
extracorporeal removal of, 185
Parkinson's disease and, 123
withdrawal from, 358-59
(+)-4-Propyl-9-hydroxynaphthoxazine
Parkinson's disease and, 123
Prostaglandins
interleukin-1 and, 26
platelet-activating factor and, 243
shock and, 302-3
Prostaglandin synthetase
polycyclic aromatic hydrocarbons and, 29
Prostanoids
shock and, 302-3
Protein kinase C
activation of, 202, 204
diacylglycerol and, 27
Protein synthesis
trichothecenes and, 39
Psoriasis
platelet-activating factor and, 247
Psychosis
levodopa syndrome and, 116
Psychotherapeutic agents
extracorporeal removal of, 184
overdose of, 169
Pulmonary edema
platelet-activating factor and, 240
Pulmonary hypertension
thromboxane A_2 and, 304
Pulmonary hypotension
platelet-activating factor and, 240
Pulmonary thrombosis
thromboxane A_2 and, 303
Purine nucleosides
adenosine receptors and, 315
Purine receptors, 315-35
Pyrazole
glycol ethers and, 412
Pyrazoloquinolines
benzodiazepine receptor and, 328
Pyrenes
diesel exhaust and, 281
Pyruvate carboxylase
acetyl-CoA and, 259

Q

Quantum mechanics
computer-aided drug design and, 205-6
Quinidine
extracorporeal removal of, 185
Quinones
benzene metabolism and, 400

R

Rauwolscine
adrenergic receptors and, 221
REM sleep
acetylcholine and, 139-46
adenosine and, 329
cholinergic regulation of, 137-49
Renal disease
gold and, 32
Renin
adenosine agonists and, 335
aspartyl proteases and, 198
Reserpine
cardiac β-adrenoceptors and, 359
Huntington's disease and, 127
Respiration
adenosine and, 334
Respiratory disease
platelet-activating factor and, 246
Respiratory distress syndrome
carnitine and, 267
Respiratory tract cancer
diesel exhaust particles and, 285-88

Reticuloendothelial system
diethylstilbestrol and, 36
Reye's syndrome
carnitine deficiency and, 264-66
Rheumatoid arthritis, 80
Rhodopsin
transducin and, 375-76
Rice-oil disease, 92, 98-103
RNA synthesis
activated B cells and, 27

S

Saccharomyces cerevisiae
adenylyl cyclase system of, 378-79
Salicylates
extracorporeal removal of, 183
overdose of, 169
Salmonella typhimurium
methylparathion and, 37
Salmonella typhimurium assay
diesel exhaust particles and, 279-81
Schizophrenia
REM latency and, 147
Scopolamine
affective disorders and, 148
Huntington's disease and, 126
REM sleep and, 144
Sedative agents
extracorporeal removal of, 181-83
Selenium
extracorporeal removal of, 186
Self-mutilation
adenosine and, 331
Seminal fluid
inhibin from, 4-10
Semiquinones
benzene metabolism and, 400
Septic shock
platelet-activating factor and, 246
thromboxane A_2 and, 303
Serotonin
calcium channels and, 352
norepinephrine storage vesicles and, 52
ponto-geniculo-occipital waves and, 141
REM sleep and, 143
Serum sickness
platelet-activating factor and, 238, 246
Shale dust
lung cancer and, 287
Shock
leukotrienes and, 304-5
platelet-activating factor and, 305-9
prostaglandins and, 302-3
thromboxane A_2 and, 303-4
vasoactive lipids and, 301-10
Sickle cell anemia, 194
Silica
immunotoxicity of, 40-41
Silicon
diesel exhaust particles and, 280
Silicosis, 40-41
Skeletal muscle
carnitine levels in, 260
Sleep
adenosine and, 329
REM
acetylcholine and, 139-46
adenosine and, 329
cholinergic regulation of, 137-49
Sodium valproate
Huntington's disease and, 127
Solvent toxicology, 399-419
Somatostatin
calcium channels and, 352
cotransmission of, 55-56
Spasmodic torticollis
drugs affecting, 124-25
Spasmolytic agents
extracorporeal removal of, 186
Squamous cell carcinoma
diesel exhaust and, 287
Steroids
adrenergic receptors and, 229
binding of, 196
Subacute myelo-optic-neuropathy
clioquinol and, 71
Substance P-IR
cotransmission of, 58
Sulfanilamide
adverse drug reactions and, 71
Sulfonamides
carbonic anhydrase and, 195
Sulfur
diesel exhaust particles and, 280
Supraventricular tachycardia
adenosine and, 331
calcium channel blockers and, 347
Sympathetic ganglia
cotransmission in, 54-55
Sympathetic neurons
cotransmission in, 53-54
Syncope
prazosin and, 80
Syphilis
treatment of, 431
Systemic injection test
polymer materials and, 160-61
Systemic lupus erythematosus
platelet-activating factor and, 247

T

Tachycardia
adenosine and, 331
calcium channel blockers and, 347
Tamoxiphen
estrogen receptors and, 36
T cells
activation of
benzene derivatives and, 37
asbestosis and, 40
development of, 27-28
growth-promoting factors and, 27
interleukin-1 synthesis and, 26
organotins and, 34
polycyclic aromatic hydrocarbons and, 29
proliferation of
lead exposure and, 33
2,3,7,8-tetrachlorodibenzo-*p*-dioxin and, 31
See also Cytotoxic T cells; T helper cells; T suppressor cells
Teleocidin B
tumor-promoting activity of, 203-4
Tendamistat
crystal structure of, 194
Teratogenicity
glycol ethers and, 413-15
Terpenoids
platelet-activating factor and, 244
Testes
glycol ethers and, 410-12
inhibin and, 17
Testosterone
immunotoxicity of, 35
Tetrabenazine
dystonic syndromes and, 125
Gilles de la Tourette's syndrome and, 128
Huntington's disease and, 127
3,4,3',4'-Tetrachlorobiphenyl, 101
2,3,7,8-Tetrachlorodibenzodioxin, 88
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin
immunological effects of, 30-32
2,3,7,8-Tetrachlorodibenzofuran, 99

Tetradecylglycidic acid
long-chain fatty acids and, 270
Tetrahydrocannabinol
immunotoxicity of, 35
Tetrahydroisoxazolo-5,4-6-pyridin-3-ol
Huntington's disease and, 127
Thalidomide
adverse drug reactions and, 71
T helper cells
estrogens and, 36
functions of, 27
interleukin-2 and, 27
polycyclic aromatic hydrocarbons and, 29
Theophylline
bronchodilation and, 332-33
convulsant activity of, 330
cyclic AMP and, 316
extracorporeal removal of, 186
stress-related events and, 333
Thermolysin
mechanism of action of, 195
Thiols
lymphocytes and, 33-34
Thrombocytopenia
benzene exposure and, 37-38, 400
platelet-activating factor and, 238, 240, 246
Thromboembolism
oral contraceptives and, 77
Thymocytes
2,3,7,8-tetrachlorodibenzo-*p*-dioxin and, 32
Thymosin
estrogens and, 36
Thyroid hormones
binding of, 197
Thyrotropin-releasing hormone
leukotriene-induced hypotension and, 305
minimum energy conformers for, 204
platelet-activating factor and, 240, 243
Tiapamil, 347
Ticrynafen
adverse drug reactions and, 71
Tin
toxicity of, 159
Titanium dioxide
lung cancer and, 287
Titanium tetrachloride
lung cancer and, 288
Tocainide
extracorporeal removal of, 185
Toluene
benzene metabolism and, 401
Torsion dystonia
drugs affecting, 124-25
Toxic oil syndrome, 24
Toxicology
risk assessment in, 432-33
Transducin
rhodopsin and, 375-76
Trauma
leukotrienes and, 304-5
platelet-activating factor and, 305-9
thromboxane A_2 and, 303-4
Traumatic shock
lipoxygenase pathway inhibitors and, 305
prostaglandins and, 302
thromboxane A_2 and, 303
Traveler's diarrhea, 71
Triazolobenzodiazepines
platelet-activating factor and, 243-44
Triazoloquinazolines
adenosine receptors and, 318, 328
Trichothecenes
immunotoxicity of, 38-39
Trientine dihydrochloride
Wilson's disease and, 129
Trihexyphenidyl
dystonic syndromes and, 125
Parkinson's disease and, 119
O,O,S-Trimethylphosphorothioate
immunotoxicity of, 37
Trypsin
structure of, 195
T suppressor cells
estrogens and, 36
functions of, 27
Tuberculosis
benzene exposure and, 38
treatment of, 431
Tumors
benzidine and, 35
diesel exhaust and, 286-88
inflammatory macrophages and, 26
polychlorinated biphenyls and, 93
Tunicamycin
adrenergic receptors and, 226
Tyrosine hydroxylase
adenosine and, 326

U

Urinary incontinence
calcium channel blockers and, 347

V

Valproic acid
extracorporeal removal of, 184
Reye's-like syndromes and, 265
Vasoactive intestinal peptide
cotransmission of, 56-57, 61-62
Vasoactive lipids
shock and, 301-10
Vasoconstriction
thromboxane A_2 and, 303
Verapamil, 347-48
binding sites for, 355
conotoxins and, 352
withdrawal from, 359

W

Wilson's disease
drugs affecting, 128-29

X

Xanthines
adenosine and, 327-28
arrhythmias and, 332
cyclic AMP and, 316
morphine analgesia and, 330
Xenobiotics, 23
estrogenic, 35-36
immunotoxic, 28-41
specificity of, 25
teratogenicity of, 24
X-ray crystallography
macromolecules and, 193-94
Xylene
benzene metabolism and, 401

Y

Yeast
adenylyl cyclase system of, 378-79
Yohimbine
adrenergic receptors and, 221
Yucheng, 98-103
Yusho, 92, 98-103

Z

Zearalenol
immunotoxicity of, 35
Zearalenone
immunotoxicity of, 35
Zinc
diesel exhaust particles and, 280
extracorporeal removal of, 186
Zinc salts
Wilson's disease and, 129
Zomepirac
adverse drug reactions and, 71